BioCentury
ARTICLE | Company News

Ipsen, Nestle deal

January 25, 2016 8:00 AM UTC

Ipsen and Nestle’s Galderma unit again amended a 2007 deal. Ipsen now granted Galderma exclusive rights to develop and commercialize Dysport abobotulinumtoxinA for aesthetic use in China, India, Sout...